Skip to main content

Table 2 The details of treatments provided

From: Optimal timing of introducing mobilization therapy for ICU patients with sepsis

Treatments All patients (n = 296) Patients in the EM group (n = 96) Patients in the non-EM group (n = 200) P-value
Management of respiratory and circulatory dynamics
 Invasive mechanical ventilation, n (%) 199 (67%) 59 (61%) 140 (70%) 0.15
 ECMO, n (%) 17 (6%) 4 (4%) 13 (7%) 0.59
  VA-ECMO 6 (2%) 0 (0%) 6 (3%) 0.18
  VV-ECMO 11 (4%) 4 (4%) 7 (4%) 0.75
 Renal dialysis, n (%) 94 (32%) 26 (27%) 68 (34%) 0.29
Medication treatment
 Corticosteroid, n (%) 71 (24%) 20 (21%) 50 (25%) 0.47
 Neuromuscular blocking agent, n (%) 8 (3%) 1 (1%) 7 (4%) 0.44
Analgesia and sedation
 Continuous analgesia (fentanyl), n (%) 204 (69%) 63 (66%) 141 (71%) 0.35
 Fentanyl duration (day), median [IQR] 2.6 [1.4–4.8] 2.0 [1.3–3.2] 3.5 [1.6–5.7] 0.05
  Mean fentanyl dose (µg/h), median [IQR] 25.0 [21.0–36.2] 25.8 [21.3–39.2] 25.0 [20.9–35.1] 0.71
 Continuous sedation, n (%) 201 (68%) 61 (63%) 140 (70.0%) 0.23
  Total sedation duration (day), median [IQR] 2.4 [1.3–4.7] 1.7 [1.1–2.6] 2.7 [1.4–6.3] 0.04
  Use of benzodiazepines, n (%) 93 (31%) 20 (21%) 73 (37%) < 0.01
  Mean benzodiazepine dose (mg/h), median [IQR] 4.4 [2.7–5.4] 5.0 [3.1–5.7] 4.0 [2.6–5.2] < 0.01
  Use of propofol, n (%) 136 (46%) 42 (44%) 94 (47%) 0.62
  Mean propofol dose (mg/h), median [IQR] 50.7 [39.5–68.4] 50.9 [37.4–78.2] 49.4 [40.0–66.8] 0.50
  Use of dexmedetomidine, n (%) 145 (49%) 43 (45%) 102 (51%) 0.32
  Mean dexmedetomidine dose (µg/h), median [IQR] 16.2 [12.0–22.8] 18.0 [13.0–22.9] 16.0 [12.0–21.2] 0.70
Vasopressor
 Continuous vasopressor, n (%) 230 (78%) 70 (73%) 160 (80%) 0.18
  Use of norepinephrine, n (%) 221 (75%) 66 (69%) 155 (78%) 0.12
  Mean norepinephrine dose (10–1 µg/kg/min), median [IQR] 1.5 [1.0–2.2] 1.5 [0.8–2.1] 1.5 [1.1–2.4] 0.89
  Use of dopamine, n (%) 112 (38%) 26 (27%) 86 (43%) 0.01
   Mean dopamine dose (µg/kg/min), median [IQR] 4.0 [2.9–5.3] 4.0 [2.9–4.4] 4.0 [3.0–5.5] < 0.01
  Use of dobutamine, n (%) 50 (17%) 9 (9%) 41 (21%) 0.02
   Mean dobutamine dose (µg/kg/min), median [IQR] 3.2 [2.3–4.7] 2.3 [2.0–2.7] 3.7 [2.6–5.2] < 0.01
  Use of epinepheline, n (%) 16 (5%) 3 (3%) 13 (7%) 0.28
   Mean epinepheline dose (10–1 µg/kg/min), median [IQR] 1.1 [0.9–1.3] 0.9 [0.9–1.0] 1.2 [1.0–1.4] < 0.01
  Use of vasopressin, n (%) 51 (17%) 12 (13%) 39 (20%) 0.14
   Mean vasopressin dose (units/h), median [IQR] 1.2 [1.0–1.7] 1.5 [1.2–1.7] 1.0 [0.9–1.7] < 0.01
  1. ECMO extracorporeal membrane oxygenation, EM early mobilization, VA venoarterial, VV venovenous